Tailoring treatments using treatment effect modification by Schmidt, AF et al.
1 
 
Tailoring Treatments using Treatment Effect Modification.  
A F Schmidta,b,c,d*, O H Klungela,b, M Nielenc, A de Boerb, R H H Groenwolda,b, A W 
Hoesa. 
 
a. Julius Center for Health Sciences and Primary Care, University Medical Center 
Utrecht, P.O. Box 85500, 3508 GA Utrecht, the Netherlands. 
b. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for 
Pharmaceutical Sciences, P.O. Box 80082, 3508 TB Utrecht, The Netherlands. 
c. Department of Farm Animal Health, Faculty of Veterinary Medicine, Utrecht 
University, Yalelaan 7, Utrecht 3584 CL, The Netherlands. 
d. Institute of Cardiovascular Science, Faculty of Population Health, University College 
London, London WC1E 6BT, the United Kingdom. 
 
* Contact: 0044 (0)20 3549 5625  
E-mail address: amand.schmidt@ucl.ac.uk (A.F.Schmidt). 
 
Running title: Tailoring treatment. 
Word count text: 3336 
Word count abstract: 172  
Number of references: 69 
Number of tables: 1 
Number of figures: 2 
Keywords: Randomized controlled trial; nonrandomized study design; observational 
study design; statistics, effect modification, interaction, generalizability. 
2 
 
 
Conflict of interest statement 
None of the authors of this paper have a financial or personal relationship with other 
people or organisations that could inappropriately influence or bias the content of the 
paper. 
 
Author contributions 
AFS drafted the manuscript. OHK, MN, AB, AWH and RHHG provided guidance during 
initial planning of the paper and during critical revision.  
 
Acknowledgements 
This work was supported by Research Focus Areas funding of the Utrecht University, 
which is a collaboration between the faculties of medicine, science, and veterinary 
medicine. The funding body had no role in decisions on the design, writing or 
submission of the manuscript. We want to acknowledge and thank the two anonymous 
reviewers for their helpful suggestions which markedly improved the manuscript.  
 
Prior postings and presentations 
This study and its results have not been previously published, neither has it been 
presented at conferences.  
3 
 
 
Key Points 
 Clinical studies are designed to provide evidence on average treatment effects. 
 To tailor treatment towards individual patients, the presence or absence of 
treatment effect modification needs to be systematically elucidated.  
 Generalizability of treatment effects can be tested within the framework of 
equivalence testing.  
 The type of patient, the presence, the magnitude, and the number of effect 
modifiers determines whether no further analyses, univariable subgroup 
analyses, or multivariable subgroup analyses may need to be performed.   
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Abstract 
Applying results from clinical studies to individual patients can be a difficult process. 
Using the concept of treatment effect modification (also referred to as interaction), 
defined as a difference in treatment response between patient groups, we discuss 
whether and how treatment effects can be tailored to better meet patients’ needs. First 
we argue that, contrary to how most studies are designed, treatment effect modification 
should be expected. Second, given this expected heterogeneity, a small number of 
clinically relevant subgroups should be a priori selected, depending on the expected 
magnitude of effect modification, and prevalence of the patient type. Third, by defining 
generalizability as the absence of treatment effect modification we show that 
generalizability can be evaluated within the usual statistical framework of equivalence 
testing. Fourth, when equivalence cannot be confirmed, we address the need for further 
analyses, and studies tailoring treatment towards groups of patients with similar 
response to treatment. Fifth, we argue that to properly frame, the entire body of 
evidence on effect modification should be quantified in a prior probability.   
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Background 
Before launching a new treatment on the market, medical interventions and most notably 
drugs, are typically evaluated in randomized clinical trials (RCTs) which primarily focus 
on the intended effects of interventions. Sometimes, RCTs can also provide information 
on relatively common unintended (i.e. adverse) effects1-3. After marketing, intervention 
effects (both intended and unintended) are often monitored using nonrandomized 
studies (e.g., case-control or cohort studies), supplemented by post-launch RCTs when 
needed. These studies are usually designed to provide information on the average 
intervention effect. Therefore, differences in treatment effects between a wide range of 
potential users will often remain undetected4-7.  
 
When treatment effects differ between patients, this is referred to as effect modification, 
interaction, or heterogeneity of treatment effects. Consider a hypothetical trial (Table 1) 
that includes patients with diabetes (40%) and patients without (60%). The risk ratio 
(RR) of the intervention effect on the 5-years incidence of stroke, differs between 
patients with and without diabetes: e.g. RR= 0.75 among patients with diabetes and RR 
= 0.63 among patients without diabetes. The observed (average) intervention effect is a 
weighted average of the effects among patients with and patients without diabetes: RR = 
0.68. In this example, the intervention effect differs between subgroups based on 
diabetes status, i.e., there is effect modification by diabetes. Patients may be treated 
suboptimally when effect modification is not recognized. 
 
Throughout this paper, we will use the term effect modification, interaction and 
heterogeneity interchangeably. Some reserve the term interaction for the specific 
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situation of heterogeneity of treatment effect when a factor biologically interacts with the 
treatment and effect modification for the situation where it does not8. This distinction can 
usually not be determined analytically and will not be made here either. Also, it has been 
recognized that the presence of effect modification depends on the effect measure 
chosen9-11. In the example RCT (table 1) there was interaction on the RR (and on the 
risk difference [RD]) scale, however using the odds ratio (OR) the effect of treatment 
was 0.25, in both diabetic and non-diabetic patients12. Effect modification is therefore 
also referred to as effect measure modification. Here, we consider situations where the 
effect measure was selected a priori and thus only consider effect modification of the 
particular effect measure chosen.  
 
In this paper we build upon work by others4;13-15, and use the concept of treatment effect 
modification to discuss how generalizability of treatment effects can evaluated, and, if 
generalizability is absent, how to tailor effects to patients with a more homogenous 
treatment response.  
 
Should treatment effect modification be expected?  
Most clinical studies are not designed to detect treatment effect modification and usually 
assume homogeneity of treatment effects16. Because of this, power to detect interaction 
effects is generally low, and absence of significant interaction effects should not be seen 
as proof for the absence of treatment effect modification (a point we will revisit). Despite 
this expected low power, Poole, Shrier and VanderWeele17 describe that between 34% 
to 47% of the meta-analyses reviewed by Engels et.al.18, Deeks19 and Sterne and 
Egger20, rejected homogeneity of treatment effects. This, perhaps unexpected, high 
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percentage of heterogeneity is likely not solely attributable to differences in treatment 
response but may also be explained by between study differences in dosage, adherence 
strategies or co-medication (see Sun et.al.13;21 and Rothwell22, for a more complete 
discussion).  
 
Given the above mentioned problems of empirical evidence for treatment effect 
heterogeneity we refer to theoretical work of Greenland who showed that if both 
treatment and a potential effect modifier have an effect on the outcome, treatment effect 
modification must be present on at least one effect measure scale23 (e.g., RD or RR). 
Given that most human diseases are complex in nature, multiple factors will be involved 
in a wide range of endpoints. Combining this with the tendency of more representative 
studies24;25, and therefore more heterogeneous patient samples, we feel that some 
degree of treatment effect modification should be expected in most studies in which 
treatment has an effect on an outcome.. Whether this effect modification is relevant for 
clinical practice, is a difficult question, which should be explored case by case.  
 
Which potential effect modifiers to pre-specify.  
An essential question when designing a study is for whom we want to assess the effects 
of treatment, whether treatment effects may differ, and if so what defines the subgroups 
for which treatment effects may differ. To pre-specify potential effect modifier it seems 
sensible to take account of any prior knowledge of the biological mechanism, potential 
patient benefit, the frequency certain patients are encountered in practice, and the costs 
involved in measuring a patient characteristic. When e.g. comorbidity is a potential effect 
modifier, it seems more reasonable to assess whether relatively common diseases, such 
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as diabetes, modify the effect of treatment. Discussions on the choice of subgroups 
should focus on patients included but also certainly on patients not included in a (future) 
study26.  
 
Too often, however, discussions on generalizability or the absence of treatment effect 
modification revolve around the question whether a patient sample is representative of 
the target population or the “average” patient27. Representativeness however, plays only 
a minor role in applying treatment effects to individuals14;25;28;29. In the absence of effect 
modification the same treatment effect applies to every patient subgroup, and thus, 
representativeness is irrelevant. In the presence of treatment effect modification, due to 
unequal subgroup sizes, a representative sample will more often than not preclude 
detection of treatment effect modification. Hence, representativeness often results in 
wrongfully assuming homogeneity of treatment effects and thus possibly in patients 
being treated suboptimally. A more fruitful approach when expecting treatment effect 
modification is to design a study to oversample the pre-specified patient subgroups to 
ensure sufficient power to detect interaction or its absence.  
 
Even if one is interested in population average treatment effect30 one should be aware 
that in the presence of treatment effect modification, small differences between 
populations can result in markedly different main treatment effects31. Assume, for 
example that, in a population aged 65, the main treatment effect is 1.00 (RR). In the 
presence of an interaction effect of 0.95 (RR) per year, the treatment effect in a 
population aged 70 will be 0.77 (RR) [i.e., 𝑒ln(1.00)+ln(0.95)∗(70−65) ≈ 0.77]. Hence, unless 
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treatment effect modification is minimal, population average treatment effects are not 
expected to generalize to other settings.  
 
Thus, when discussing generalizability or treatment effect modification, it is essential to 
define the patient group(s) of interest. Such subgroups should be chosen based on 
biological plausibility, potential patient benefit, subgroup frequency, and measurement 
costs, this should, however, not be guided by the issue of representativeness.  
 
When are treatment effects generalizable? 
When interaction effects can be quantified with sufficient precision to exclude clinically 
relevant treatment effect modification, the main (i.e. average) treatment effect equally 
applies to all subjects studied and - because there is no direct reason to believe the 
treatment acts differently in other subjects – this treatment effect is possibly 
generalizable to, and perhaps beyond, the population included in the study30;31. As 
stated previously non-significant interaction tests are not sufficient to claim 
generalizability; to quote Altman32 “absence of evidence is not evidence of absence”. 
Instead to ‘prove’ generalizability, so called equivalence tests should be used. 
 
Recognizing that the strict null-hypothesis (i.e., H0: μ0 = null) probably never holds, tests 
of equivalence determine margins between which differences in treatment effect 
estimates are small enough to be deemed clinically irrelevant33;34. When the treatment 
effect estimate and its confidence interval fall between these margins, equivalence is 
‘proven’ (Figure 1). Equivalence tests can be applied to interactions effects by 
determining a margin around the neutral interaction effect or around the subgroup 
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specific effects, and testing if both the point estimates and their confidence intervals fall 
within this margin. For example, let 𝑑 be the predefined margin of equivalence, 𝛿𝑖 the 
effect for the 𝑖𝑡ℎ subgroup, when 𝑖 = {0,1} the interaction effects equals 𝜃 = 𝛿0 − 𝛿1, 𝜎𝑖 
the subgroup specific standard errors of 𝛿𝑖, and 𝜎𝜃 the standard error of the interaction 
effect. In this case an interaction effect is sufficiently absent when (𝛿𝑖 − 𝑧 ∗ 𝜎𝑖, 𝛿𝑖 + 𝑧 ∗
𝜎𝑖) ⊂ (−𝑑, 𝑑) is true for all subgroup effects or (𝜃 − 𝑧 ∗ 𝜎𝜃, 𝜃 + 𝑧 ∗ 𝜎𝜃) ⊂ (−𝑑, 𝑑), where 
𝑧 =  𝜙−1 (1 −
𝛼
2𝑘
), with typically 𝛼 = 0.05 and 𝑘 equalling the number of subgroups or 1 if 
using an interaction effect. These procedures test against the following null-hypotheses 
𝐻0: |𝛿𝑖| < 𝑑 and 𝐻0: |𝜃| < 𝑑. The subgroup specific equivalence test is appealing 
because it requires complete equivalence in every subgroup, however as shown in 
Figure 2 power is likely low. Using the same margin as for the subgroup specific effects, 
an interaction equivalence test is more powerful (Figure 2). However, when using the 
interaction equivalence test with more than 2 underlying subgroups, some subgroup 
specific effects may violate the equivalence margins which may be undesirable. A clear 
benefit of the interaction equivalence tests over its subgroup specific counter parts is 
that it straightforwardly extends to linear effect modifiers (e.g., age), preventing arbitrary 
categorizations.  
 
Detecting treatment effect modification.  
Effect modification can be detected by testing whether the interaction effect differs from 
zero35;36. However, such interaction tests are renowned for their lack of power (i.e., the 
probability of correctly concluding that an interaction exists) which may be compounded 
by large type 1 errors (i.e., the probability of falsely concluding that an interaction exists) 
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when the data are sparse10;37-43. Note, data sparseness is intuitively defined as a small 
expected cell count but generalizes to continuous data with low densities (or 
frequencies) at certain values. Often this underperformance of interaction tests is viewed 
as inevitable; however, this underperformance is merely a result of a lack of a proper 
design to detect interaction effect; often resulting in sparse data. 
 
For more definitive conclusions on the absence or presence of treatment effect 
modification, the current approach to interaction testing needs improvement. A first step 
is to more actively share and pool individual patient data to increase the effective sample 
size, power, and by decreasing data sparseness, ensuring nominal type 1 error rates for 
interaction tests31;44;45.  
 
Second, for interaction tests to be anything but exploratory, interaction tests should not 
only be pre-specified but also include proper sample size calculations and sampling 
strategies (e.g., equally sized subgroups); ensuring appropriate power and type 1 error 
rates. One attractive idea is to incorporate interaction tests using adaptive trial designs46-
48. For example, consider an RCT of a particular treatment, conducted within a 
homogenous group of patients. If during interim analysis there is enough evidence to 
expect that the treatment is effective (i.e. there is a beneficial average effect), the 
second study period (the period following the interim analysis) can be used to enrich the 
patient sample to explore heterogeneity between pre-specified clinically important 
patient subgroups. We recognize that this contrasts with the more usual approach of 
focusing on a single promising subgroup after interim46;49. Here we actually reverse the 
usual approach; we start with a subgroup where we expect treatment to be most 
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beneficial and in the second stage (after interim) explore consistency of this treatment 
effect across important subgroups.  
 
Third, to increase the interpretability of interaction tests (or any test) we feel it is 
essential to a priori define the prior probability of rejecting a test. For example let’s 
assume that data from multiple well designed studies are available, ensuring sufficient 
power (let’s say 70%, or type 2 error rate of 0.30) to reject an interaction test using a 
statistical significance level (alpha) of 0.05. Suppose two different drug compounds are 
evaluated, for the first compound we know that for a similar drug 1% of interaction test 
were true positives, for the second compound this was 25%. In the first case the 
probability that a rejected interaction test reflects a true positive equals 1 −
𝛼(1−𝑝𝑟𝑖𝑜𝑟)
𝛼(1−𝑝𝑟𝑖𝑜𝑟)+𝑝𝑟𝑖𝑜𝑟(1−𝛽)
=  1 −
0.05(1−0.01)
0.05(1−0.01)+0.01(1−0.30)
= 0.13, while for the second compound 
this equals 0.82. Quantifying a prior probability is of course inherently subjective an 
issue which we address later.  
 
How to personalize treatment effects. 
We suggest that after one identifies important potential effect modifiers (based on the 
criteria discussed), and quantifying the available prior knowledge, one explores if 
generalizability can be shown. If generalizability cannot be proven, we propose a 
thorough multivariable analyses to explore for which patients treatment needs to be 
modified.  
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To explore generalizability one first needs to define regions of equivalence as discussed 
above. After which pre-specified interaction tests can be compared against this region. 
In itself pre-specification does not significantly increase power to detect interactions 
unless proper design steps are taken (e.g., oversampling of subgroups)50. We suggest 
that, regardless of pre-specification or not, these interaction tests are deemed 
exploratory unless steps are made to quantify the prior evidence, ensure sufficient 
sample size, power, and type 1 error levels.  
 
After determining the amount of within study heterogeneity, and assuming multiple 
studies exist, between study heterogeneity should be explored, for example by 
comparing  aggregated results from different studies44;51. However, attributing 
differences in treatment effects between studies to differences in baseline characteristics 
or study design, using for example meta-regression, may result in (ecological) bias. 
Therefore, significant interaction effects found in aggregated meta-analyses should 
always be confirmed using individual patient data (IPD) or independently replicated.  
 
If, after performing the above analyses, absence of effect modification cannot be 
excluded with confidence, confirmatory analyses are needed, tailoring treatment effects 
towards groups or individuals. If treatment homogeneity is rejected one may be tempted 
to treat this as a true positive results. However, as with any discovery, replicating results 
is essential, hence results on interaction effects should be independently confirmed. If 
the results are replicated, it seems sensible to finally combined data from both the 
confirmatory and exploratory steps to increase precision in the subgroup specific effect 
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estimates of the treatment52, and use these to tailor treatment (e.g., RR = 0. 75 for 
diabetes patients versus RR = 0.63 in patients without diabetes).  
 
Recently, subgroup-specific estimates based on a single variable (i.e., univariable 
interactions) have been criticized15;53-56. Among other reasons, critics recognized that 
patients likely differ on more than one characteristic (i.e., there is unexplained treatment 
effect modification). A straightforward solution is to include multiple interaction tests, for 
example exploring whether treatment effects differ by diabetes, gender, and age. 
However, depending on the number of subgroups (and type, e.g., binary or not), 
exploring higher order interactions will increase data sparseness, which may 
dramatically reduce power and increase type 1 error rates10;39-42;57-62.  
 
To (partially) solve this, a two-step multivariable method has been suggested. First, a 
multivariable risk prediction model is developed, predicting the risk of the outcome if a 
subjects is not treated63;64. For example, using a logistic model, the predicted risk equals 
𝑙𝑜𝑔𝑖𝑡(?̂?𝑖) = 𝑙𝑜𝑔𝑖𝑡(𝑃𝑟𝑜𝑏[𝑌 = 1|𝑍]) =  ?̂?0 +  ∑ ?̂?𝑗𝑧𝑖𝑗
𝑘
𝑗=1  [equation 1], where Z equals a 
𝑛 𝑏𝑦 𝑘 matrix and Y a 𝑛 𝑏𝑦 1 column matrix. In the second step, the predicted risk is 
multiplied by a relative treatment effect estimate (e.g. a risk ratio) 56. Assume, for 
example, that in our previous trial the multivariable 5-years predicted risk of stroke 
without treatment equals 
1
1+𝑒−𝑙𝑜𝑔𝑖𝑡(?̂?𝑖)
=
1
1+𝑒2.20
= 0.10, for a particular patient with 
diabetes. Based on the RR of 0.75, treating this patient will result in a predicted 5 year 
risk of 0.075 (i.e., 0.75 * 0.10 = 0.075) and in an individualized RD of 0.100 – 0.075 = 
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0.025; in the general case the RD can be individualized using equation 2: 𝑅𝐷𝑖 =
𝑙𝑜𝑔𝑖𝑡(?̂?𝑖)
−1 ∗ 𝑅𝑅.  
 
While this multivariable approach to subgroup analysis is indeed an improvement, one 
should be aware, this approach is only valid if the relative treatment effect measure 
(e.g., the RR) is homogenous across different levels of the predicted risk. If unknown to 
the researcher, the relative treatment effect measure is in fact heterogeneous, applying 
the above approach may falsely induce treatment effect modification on the risk 
difference scale. We propose that when the above approach is applied, this should be 
combined by the following sensitivity analysis exploring 1) if the relative effect measure 
is heterogeneous across the range of predicted risks and 2) to what extend the RD is 
truly heterogeneous across the predicted risk. Following the risk stratification approach 
by Kent and Hayward 15 and others we suggest subdivide the subjects sample based on  
quantiles of the predicted risk (equation 1) and estimate quantile specific treatment 
effects (e.g., RR and RD)15 to explore if the treatment effects changes with increasing 
risk. Using this approach one can judge if the relative effect measure is fairly 
homogenous across the predicted risk and if individualized treatment effects on the RD 
scale (equation 2) agree with the quantile specific treatment effects on RD scale. As with 
any testing procedure one should be careful not to over interpret non-significant 
interaction tests results, because, as addressed before ,this does not imply 
homogeneity. To increase power and only if quantile specific treatment estimates 
linearly change one could use the predicted risk as a linear term in a statistical model 
and include a treatment by predicted risk interaction term65. Depending on the amount of 
linearity such a model is expected to be more precise and powerful than the quantile 
16 
 
specific approach. A remaining issue with the above described approaches is that, 
typically, the predicted risk is treated as if it was observed without error, possibly 
erroneously decreasing the standard error of any test66. A second more general 
comment is  that all the discussed multivariable approaches only allow for individualized 
treatment effect estimates in so far as variables are related to the outcome. A strategy to 
include variables unrelated with the outcome in a multivariable interaction test is to use 
unsupervised cluster analysis to identify multivariable patient clusters, and test if 
treatment effectiveness differs across cluster memberships67-69.  
 
Quantifying the prior probability of treatment effect modification. 
Throughout the previous sections we frequently emphasized the need to quantify the 
prior probability for the presence of an interaction. Here we detail what to base this prior 
probability on.  
 
As stated previously, RCTs are the gold standard in intervention research. Despite this, 
we feel strongly against a priori deciding to quantifying the prior probability solely on 
RCT results. RCTs are not initiated at random. Instead, RCTs are initiated based on 
information from basic experiments, genetic studies, nonrandomized studies and/or 
previous RCTs, therefore to properly quantify the prior knowledge these sources should 
all be considered. Depending, however, on the potential risk of bias, taking account of 
the endpoints of interest, and the general potential risk of an intervention, these multiple 
source of prior knowledge should be reweighted. In some cases, for example, when 
exploring the intended effect of statins on a myocardial infraction, one may choose to 
weight non-RCT data by zero. This reweighing or elimination of data should obviously be 
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clearly presented and justified. We appreciate that this introduces a certain amount of 
subjectivity in analyses that may seem otherwise objective. However, this is no different 
than excluding RCTs at perceived high risk of bias from a meta-analysis, a thing which 
is customarily (although not without discussion) done in, for example, cochrane reviews.  
 
Summary  
In the present commentary we have argued that detecting treatment effect modification 
is essential to bridge the gap between results from clinical studies and treating 
individuals in daily practice. We addressed strategies to detect effect modification and 
used these in a framework to assess if there is a need for more individualized treatment 
effects, and estimate this in confirmatory analyses.  
 
We conclude with the following recommendations. First, treatment effect modification 
should be formally assessed using interaction tests. Second, pre-specified subgroups 
should be selected based on biological plausibility, prevalence of the patient type and 
cost-effectiveness of determining the patient characteristic. Third, before tailoring 
treatment effects to patient subgroups one should first consider if generalizability or the 
absence of treatment effect modification can be proven, using e.g., an equivalence test. 
Fourth, for interaction tests to be anything but exploratory, these should not only be pre-
specified, but include a quantification of the prior knowledge, use proper sample size 
calculations and sampling strategies to ensure appropriate levels of power and type 1 
error rates (taking account of possible multiple testing). Finally, if after careful 
consideration and sufficient replication, subgroup effects are found to be consistent 
across different studies, this should have an impact in daily clinical practice. What is 
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sufficient evidence, however, should be determined on a case by case basis and 
depends, amongst other things, on the disease, intervention related risks and the 
magnitude of interaction. 
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Tables 
Table 1 Stroke risk by exposure (X) and baseline diabetes (D) status and their interaction on different measurement scales.  
 D = 0 D = 1  
X = 0 0.80 0.89 
X = 1 0.50 0.67 
   
Measure of risk difference 
interaction 
Measure of risk ratio interaction Measure of odds ratio interaction 
0.67 − 0.50 − 0.89 + 0.80 = 0.08  0.67 ∗ 0.80
0.50 ∗ 0.89
= 1.20 
0.67
0.33 ∗
0.80
0.20
0.89
0.11 ∗
0.50
0.50
= 1.00 
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Figure captions 
 
Figure 1. Examples of equivalence testing using confidence intervals*.  
*Based on Jones et al. 33. 
 
Figure 2. Empirical power of two test for equivalence of treatment effect 
modification*.  
 
* The dashed line with a square symbol indicates power for an equivalence test using an 
interaction effect, the dashed dotted line with the circle symbol indicates power for the 
equivalence test based on subgroup specific effects. Simulated results were based on a 
scenario (1,000 replications) with subjects treated or untreated 𝑗 = {1,0} and exposed or 
unexposed to a potential effect modifier 𝑖 = {1,0}, with the endpoint incidence equaling 
𝑟𝑖𝑗 = {0.20, 0.15, 0.15, 0.10}, and each group of 𝑖𝑗 subjects occurring 1,000 times.  
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